If you prioritize the cooperation, almost every time Google cooperates with the pharmaceutical giants, it is based on the combination of current technology and traditional pharmaceutical research and development to improve existing medical services.
An expert interviewed by Firstword said: “What Google is doing today is like a human step on the moon. Their investment in the life sciences is at the height of improving human life. By creating a parent company Alphabet and spin-off advertising business, Google can realize its own grand grand plan according to its own investment logic.”
In those years, what dream cooperation has Google conducted with large pharmaceutical companies?
In July 2014, Novartis and Google signed a cooperation agreement to jointly develop smart contact lenses that can detect blood sugar levels in diabetics through tears and at the same time help restore vision.
First of all, through the electronic technology of sensors, microchips and microbatteries, the contact lens can provide blood glucose level data once per second to achieve real-time monitoring of the patient’s blood glucose level and can be connected to an insulin pump, based on the blood glucose per second. A suitable dose of insulin is provided horizontally. More similar to playing an artificial pancreas.
Second, this contact lens can focus automatically, according to the distance of the human visual distance to automatically adjust the focal length to help users restore vision.
Novartis CEO Joseph Jimenez said that such a smart contact lens is likely to be available in 2019.
On September 18, 2013, Google announced the establishment of Calico, a company dedicated to “fighting human aging,” which was described as Google’s moon plan. In September 2014, Calico and AbbVie signed a cooperation agreement to jointly invest 1.5 billion U.S. dollars in the establishment of a research center in the San Francisco Bay Area, focusing on the development of new therapeutic drugs for age-related diseases such as neurodegenerative diseases and cancer.
Google X is another ambitious lab owned by Google. January 2015, Google X
A long-term collaboration with Biogen Idec (now Biogen) in the field of multiple sclerosis to study the continuing course of multiple sclerosis and why there are differences between patients. Google X is primarily responsible for analyzing patient data.
Multiple sclerosis is currently incurable. Different patients will have different manifestations of disease. Some may only experience temporary numbness, and some may suffer from it. Google’s interest lies in determining the reasons for this, and Biogen Idec hopes to develop more targeted therapies.
In September 2015, Google Life Science launched a partnership with Sanofi. Google expects to provide comprehensive solutions for patients through comprehensive monitoring of blood glucose levels, patient self-reporting information, medication plans, and sensor devices, while allowing doctors to easily understand the daily changes in the patient’s blood glucose in real time, so that Insulin dosage provides timely and authoritative guidance.
Johnson & Johnson
In December 2015, Verily Life Sciences and Johnson & Johnson teamed up to establish a new company for R&D-assisted surgical robots – Verb Surgical, Verily, and Johnson & Johnson, each with a 50% stake. The specific investment amount has not been disclosed.
Johnson & Johnson is a medical device giant. Through its cooperation with Google, the latter can gain powerful guidance in machine learning and image processing.
The establishment of Galvani Bioelectronics, a joint venture with GSK, should be the most ambitious cooperation between Google and pharmaceutical companies. Both parties expect to influence human electrophysiological signals by implanting computerized micro devices in the human body in order to treat diseases such as arthritis, diabetes and asthma.
If it can be successful, this may be the third treatment method in addition to drug treatment and vaccine prevention. In fact, GSK began investing in the field of electronic biology as early as 2012, and published related papers in Nature, and is a pioneer in this field.
GSK and Google have also established a seven-year plan and hope to submit applications for listing of related products to regulatory agencies by 2023.